{"id":75414,"date":"2020-10-02T01:00:00","date_gmt":"2020-10-02T01:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2736853"},"modified":"2020-10-02T01:00:00","modified_gmt":"2020-10-02T01:00:00","slug":"general-anxiety-disorder-market-set-for-rapid-growth-to-reach-around-usd-3775-million-in-2020","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2020\/10\/02\/general-anxiety-disorder-market-set-for-rapid-growth-to-reach-around-usd-3775-million-in-2020\/","title":{"rendered":"General Anxiety Disorder Market Set for Rapid Growth to Reach Around USD 3,775 Million in 2020"},"content":{"rendered":"

With the presence of a large pool of participants, the global market for general anxiety disorder is displaying a highly competitive business landscape, finds a new research report by Zion Market Research (ZMR). Johnson & Johnson, Pfizer Inc., Sanofi S.A., H. Lundbeck A\/S, Eli Lilly and Company, and Merck & Co. are few key vendors of pharmaceutical drugs for general anxiety disorder across the world. These players are focusing aggressively on innovation, as well as on including advanced technologies in their existing products. Over the coming years, they are also expected to take up partnerships and mergers and acquisitions as their key strategy for business development, states the market study.<\/p>\n

As estimated in this report, theGlobal general anxiety disorder market<\/a><\/strong>stood at US$ 3,251 million in 2014. Witnessing a tremendous rise during the period from 2015 to 2020, the revenue in this market is expected to reach US$ 3,775 million by the end of the forecast period.<\/p>\n

\"GlobalGet Free Sample Of Report –<\/strong>https:\/\/www.zionmarketresearch.com\/sample\/general-anxiety-disorder-market<\/a><\/p>\n

Rising Incidence Of Anxiety Disorders And Depression To Impel Market Growth<\/strong><\/p>\n

“Surging geriatric population prone to anxiety disorders along with the introduction of new therapies for treating the ailment is predicted to drive general anxiety disorder market expansion,” says the author of this study. In addition to this, the introduction of new therapies used for treating general anxiety disorders are also expected to succor the market trends.<\/p>\n

Today, general anxiety disorder market is witnessing a decline, subject to low supply of new drugs, expiry of key antidepressant drugs patents, and rise in the number of cost-effective generic drugs in the market.<\/p>\n

Prevalence Of Anxiety-related Ailments To Help North America Dominate Regional Market<\/strong><\/p>\n

Regionally, North America has been leading the global general anxiety disorder market and is predicted to maintain its domination over the next few years, states market study. In 2014, North America evolved as the key regional market, owing to large population infected as a result of depression & anxiety disorders. The presence of large & small pharmaceutical companies in North America is another significant factor that is supporting the growth of this regional market.<\/p>\n

The U.S. accounts for a major share of anxiety disorder therapeutics sector across the globe and can be credited for the dominant position of North America across the general anxiety disorder market. The presence of both large<\/p>\n

Furthermore, as per the reports of anxiety and depression association of America, general anxiety disorder severely affects 3.1% of the population in the U.S. This is anticipated to create lucrative opportunities for the market players to explore U.S. general anxiety disorder market as well as establish a strong presence in the region.<\/p>\n

The global general anxiety disorder market is segmented as follows:<\/p>\n

By Therapeutics<\/strong><\/p>\n